This review highlights the need for enhancements in doxorubicin chemistry, delivery, and toxicity management to prolong its clinical utility against cancer.
Should not yet alter doxorubicin use in oncology; leaves open targeted chemistry and delivery enhancements for prospective trials.
Overall the future for the continued use of doxorubicin clinically against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chemistry, delivery and toxicity. Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.
No takes yet. Share an insight, caveat, or question.
Tacar et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: